TY  - GEN
N2  - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this interaction network and identify therapeutic targets. Tyrosine kinase inhibitors (TKI) are a class of molecularly targeted therapeutics seeking to inhibit signaling pathways critical to sustaining prolifierative signaling, resisting cell death, and the other hallmarks of cancer. While tumors may initially respond to TKI therapy, disease progression is inevitable due to mechanisms of acquired resistance largely involving cellular signaling pathway reprogramming. With the ultimate goal of improved molecularly targeted therapeutic efficacy, our group has developed intracellular paired agent imaging (iPAI) to quantify drug target intereactions and oligonucleotide conjugated antibody (Ab-oligo) cyclic immunofluorescence (cycIF) imaging to characterize perturbed signaling pathways in response to therapy.
DO  - 10.6083/bc386j919
DO  - DOI
AB  - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and cross talk between signaling pathways. Advances in molecular characterization technologies such as next generation sequencing have helped unravel this interaction network and identify therapeutic targets. Tyrosine kinase inhibitors (TKI) are a class of molecularly targeted therapeutics seeking to inhibit signaling pathways critical to sustaining prolifierative signaling, resisting cell death, and the other hallmarks of cancer. While tumors may initially respond to TKI therapy, disease progression is inevitable due to mechanisms of acquired resistance largely involving cellular signaling pathway reprogramming. With the ultimate goal of improved molecularly targeted therapeutic efficacy, our group has developed intracellular paired agent imaging (iPAI) to quantify drug target intereactions and oligonucleotide conjugated antibody (Ab-oligo) cyclic immunofluorescence (cycIF) imaging to characterize perturbed signaling pathways in response to therapy.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
T1  - Fluorescence imaging technologies for in situ measurement of drug target engagement and cell signaling pathway reprogramming
DA  - 2020
AU  - McMahon, Nathan
AU  - Solanki, Allison
AU  - Jones, Jocelyn
AU  - Wang, Lei
AU  - Tichauer, Kenneth
AU  - Samkoe, Kimberly
AU  - Gibbs, Summer L.
L1  - https://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2020
ID  - 8338
L4  - https://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
KW  - Fluorescence
KW  - Tyrosine Protein Kinase Inhibitors
KW  - cancer
KW  - cyclic immunofluorescence
KW  - intracellular paired agent imaging
KW  - oligonucleotide conjugated antibody
KW  - fluorescent tagging
TI  - Fluorescence imaging technologies for in situ measurement of drug target engagement and cell signaling pathway reprogramming
Y1  - 2020
L2  - https://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
LK  - https://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
UR  - https://digitalcollections.ohsu.edu/record/8338/files/ResearchWeek.2020.McMahon.Nathan.pdf
ER  -